Psychemedics Corporation Announces Record Revenues And Earnings

ACTON, Mass., July 26, 2016

The Company's revenue for the quarter ended June 30, 2016 was $9.7 million versus $7.0 million for the quarter ended June 30, 2015, an increase of 39%.  Net income for the quarter ended June 30, 2016 was $1.6 million or $0.30 per diluted share, versus $252 thousand or $0.05 per diluted share, for the comparable period last year, an increase of 547%. The Company's revenue for the six months ended June 30, 2016 was $16.4 million versus $13.8 million for the six months ended June 30, 2015, an increase of 19%. Net income for the six months ended June 30, 2016 was $1.6 million or $0.30 per diluted share, versus $530 thousand or $0.10 per diluted share, for the comparable period last year, an increase of 204%.

Raymond C. Kubacki, Chairman and Chief Executive Officer, said,

"We are very pleased to report the highest revenue and earnings for any quarter in the Company's history.  The growth has been driven by our international business, specifically an opportunity in Brazil as noted below.  We also reached another milestone this quarter with 20 years of consecutive quarterly dividends. 

"We have noted since 2013 a significant opportunity in Brazil, and are very pleased to begin to see the results of our efforts and the efforts of our exclusive independent Brazilian distributor, Psychemedics Brasil. This opportunity is to compete for the testing of drugs of abuse required for professional drivers in Brazil. As of March 2016, testing for this opportunity had begun and is being phased in as some states have required additional time to implement the law.  Over the last two years, we have made significant investments in equipment, people and an additional facility to handle this business.  In the recent past, these investments have impacted earnings and required the Company to take on long term debt.   We are pleased about the very positive impact this opportunity had on the revenue and earnings this quarter.

"The Company's balance sheet remains strong with approximately $2.3 million in cash and $4.7 million of working capital.  The total equipment financing outstanding was $5.7 million as of June 30, 2016, compared to a total original amount borrowed of $8.7 million.  Our directors share our confidence in the future of Psychemedics and remain committed to rewarding shareholders and sharing the financial success of the Company with them as we grow.  Therefore, we are pleased to declare a quarterly dividend of $0.15 per share."

Psychemedics Corporation is the world's largest provider of hair testing for the detection of drugs of abuse. The Company's patented process is used by thousands of U.S. and international clients, including over 10% of the Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve Banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods.